

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Philip M. Carpenter MD	POSITION TITLE Professor of Clinical Pathology and Laboratory Medicine		
eRA COMMONS USER NAME (credential, e.g., agency login) PMCARPENTER			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	MM/YY	FIELD OF STUDY
Rice University, Houston, Texas	B.A.	1981	Biochemistry
Southwestern Medical School, Dallas, Texas	M.D.	1985	Medicine
University of California at San Diego	None	1988	Anatomic Pathology
University of California at San Diego	None	1990	Molecular Pathology

Please refer to the application instructions in order to complete sections A, B, C, and D of the Biographical Sketch.

Personal Statement:

I am an anatomic pathologist with subspecialty interests in perinatal, placental, breast and pediatric pathology. I have additional research interests in biomarker development and the role of the extracellular matrix in tumor cell migration.

Professional Appointments:

- 1982-1983 Medical Student Research Trainee, Department of Biochemistry, University of Texas Health Science Center at Dallas, Southwestern Medical School.

- 1988-1990 Postgraduate research Pathologist and Resident PMD IV, Division of Molecular Pathology, Department of Pathology, University of California, San Diego.
- 1990-1991 Assistant Pathologist, Department of Pathology, Children's Hospital and Health Center, San Diego.
- 1991-1998 Assistant Professor in Residence, Department of Pathology, School of Medicine, University of California, Irvine
- 1998-2006 Associate Professor of Clinical Pathology, Department of Pathology, School of Medicine, University of California, Irvine
- 2006- Professor of Clinical Pathology, Department of Pathology, School of Medicine, University of California, Irvine

Recent and representative publications

- Philip M. Carpenter PM, Wang-Rodriguez J, Chan O T.M., Wilczynski SP Laminin 5 Expression in Metaplastic Breast Carcinomas. *Am J Surg Pathol* 32:345-53, 2008
- Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. *Cancer*. 112:17-26 2008
- FL. Meyskens, Jr., CE. McLaren, D Pelot, S Fujikawa-Brooks, PM. Carpenter, E Hawk, G Kelloff, MJ. Lawson, J Kidao, J McCracken, CG Albers, DJ. Ahnen, DK Turgeon, S Goldschmid, P Lance, CH. Hagedorn, DL. Gillen and EW. Gerner. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial. *Cancer Prevention Res* 1: (2008)
- Carpenter PM, Dao AV, Arain ZS, Chang MK, Nguyen HP, Arain S, Wang-Rodriguez J, Kwon S-Y, Wilczynski SP. Motility Induction in Breast Carcinoma by Mammary Epithelial Laminin 332 (Laminin 5). *Mol Cancer Res* 2009 7:462-75
- .Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, Yu HJ, Nalcioglu O, Su MY. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. *Ann Surg Oncol*. 2009;16:1619-28
- Yarosh W, Barrientos T, Esmailpour T, Lin L, Carpenter PM, Osann K, Anton-Culver H, Huang T. TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. *Cancer Res*. 2008 ;68:693-9.
- Carpenter PM, Chen WP, Mendez A, McLaren CE, Su MY. Angiogenesis in the Progression of Breast Ductal Proliferations. *Int J Surg Pathol*. 2009 Apr 29
- Carpenter PM, Chen WP, Mendez A, McLaren CE, Su MY. Angiogenesis in the Progression of Breast Ductal Proliferations. *Int J Surg Pathol*. 2009 Apr 29
- Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, Yu HJ, Nalcioglu O, Su MY. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. *Ann Surg Oncol*. 2009;16:1619-28
- Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. *Cancer Cell*. 2010 ;18:23-38
- Siwa Chan, MD1, Jeon-Hor Chen, MD2, 3, Garima Agrawal, MD2, Muqing Lin, MS2 Rita S. Mehta, MD4, Philip M. Carpenter, MD5, Orhan Nalcioglu, PhD2, Min-Ying Su, PhD2 Characterization of Pure Ductal Carcinoma in Situ on Dynamic Contrast-Enhanced MR Imaging: Do Non-High Grade and High Grade Show Different Imaging Features? *Journal of Oncology Epub* 2010 Sep 21.
- Zhenyu Jia, Yipeng Wang, Anne Sawyers, Huazhen Yao, Farahnaz Rahmatpanah, XiaoQin Xia, Qiang Xu, Rebecca Pio, Tolga Turan, James Koziol, Steve Goodison, Philip Carpenter, Jessica Wang-Rodriguez, Anne Simoneau, Frank Meyskens, Manuel Sutton, Waldemar Lernhardt, Thomas Beach, Joseph Monforte, Michael McClelland, and Dan Mercola. Diagnosis of Prostate Cancer Using Differentially Expressed Genes in Stroma. *Cancer Research*. , 71, 2476-87.

Shi, Y., Farinelli, C. K., Chang, M. S., Carpenter, P. M. (2012). Left-sided gastroschisis with placenta findings: case report and literature review. *Int J Clin Exp Pathol*, 5(3).

Kwon, S.-Y., Chae, S. W., Wilczynski, S. P., Arain, A., Carpenter, P. M. (2012). Laminin 332 Expression in Breast Carcinoma. *Appl Immunohistochem Mol Morphol.*, 20(2), 159-64.

Kuzucan A, Chen JH, Bahri S, Mehta RS, Carpenter PM, Fwu PT, Yu HJ, Hsiang DJ, Lane KT, Butler JA, Feig SA, Su MY. Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile. *Clin Breast Cancer*. 2012 Apr;12(2):110-8.